Figure 2 | Scientific Reports

Figure 2

From: A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

Figure 2

Cardiovascular events in Custom SMQ with disproportionality analysis in the FAERS database (see supplementary materials S1 for PT affiliations). a, frequency of targeted adverse events in the target drug population (amivantamab-cardiovascular AEs); b, total adverse events (a + b) minus a value occurred in the target drug population; c, target total number of adverse events (a + c) minus a value; d, total adverse events in the background population (n)-a-b-c.

Back to article page